MiMeDB: Showing metabocard for 5-Hydroxy-L-tryptophan (MMDBc0047911)

Plant

Animal

Pharmaceutical

Xenobiotic

Record Information

Version

2.0

Status

Detected and Quantified

Creation Date

2021-11-23 23:14:34 UTC

Update Date

2024-10-13 06:39:16 UTC

Metabolite ID

MMDBc0047911

Metabolite Identification

Common Name

5-Hydroxy-L-tryptophan

Description

5-Hydroxy-L-tryptophan is an aromatic amino acid naturally produced by the body from the essential amino acid L-tryptophan. 5-Hydroxy-L-tryptophan is the immediate precursor of the neurotransmitter serotonin. The conversion to serotonin is catalyzed by the enzyme aromatic L-amino acid decarboxylase (EC 4.1.1.28) (AADC1 also known as DOPA decarboxylase), an essential enzyme in the metabolism of the monoamine neurotransmitters. An accumulation of 5-hydroxy-L-tryptophan in cerebrospinal fluid occurs in aromatic L-amino acid decarboxylase deficiency (AADC deficiency) (OMIM: 608643 ) accompanied by an increased excretion in the urine of the patients, which are indicative of the disorder but not specific. 5-Hydroxy-L-tryptophan is also increased in other disorders such as in Parkinson's patients with severe postural instability and gait disorders. The amount of endogenous 5-hydroxy-L-tryptophan available for serotonin synthesis depends on the availability of tryptophan and on the activity of various enzymes, especially tryptophan hydroxylase (EC 1.14.16.4), indoleamine 2,3-dioxygenase (EC 1.13.11.52), and tryptophan 2,3-dioxygenase (TDO) (EC 1.13.11.11). 5-Hydroxy-L-tryptophan has been used clinically for over 30 years. In addition to its use in the treatment of depression, the therapeutic administration of 5-hydroxy-L-tryptophan has been shown to be effective in treating a wide variety of conditions, including fibromyalgia, insomnia, binge eating associated with obesity, cerebellar ataxia, and chronic headaches. 5-Hydroxy-L-tryptophan easily crosses the blood-brain barrier and effectively increases central nervous system (CNS) synthesis of serotonin. Supplementation with 5-hydroxy-L-tryptophan is hypothesized to normalize serotonin synthesis, which is putatively related to its antidepressant properties (PMID: 9295177 , 17240182 , 16023217 ). When present in sufficiently high levels, 5-hydroxytryptophan can be a neurotoxin and a metabotoxin. A neurotoxin is a compound that disrupts or attacks neural cells or tissue. A metabotoxin is an endogenously produced metabolite that causes adverse health effects at chronically high levels. Signs and symptoms of AADC deficiency generally appear in the first year of life. Affected infants may have severe developmental delay, weak muscle tone (hypotonia), muscle stiffness, difficulty moving, and involuntary writhing movements of the limbs (athetosis). They may be lacking in energy (lethargic), feed poorly, startle easily, and have sleep disturbances. Since 5-hydroxytryptophan is a precursor to serotonin, altered levels of serotonin can accumulate in the brain, which leads to abnormal neural signalling. Infants with AADC deficiency have very low levels of neural signalling molecules while individuals who consume high levels of 5-hydroxytryptophan will have very high levels of neural signalling molecules. Both conditions can lead to vomiting, nausea, extreme drowsiness, and lethargy. 5-Hydroxytryptophan (5-HTP), also known as oxitriptan (INN) is sold over-the-counter in the United Kingdom, the United States, and Canada as a dietary supplement for use as an antidepressant, appetite suppressant, and sleep aid. It is also marketed in many European countries for the indication of major depression under trade names such as Cincofarm, Levothym, Levotonine, Oxyfan, Telesol, Tript-OH, and Triptum. Several double-blind placebo-controlled clinical trials have demonstrated the effectiveness of 5-HTP in the treatment of depression, though a lack of high-quality studies has been noted. More and larger studies are needed to determine if 5-HTP is truly effective in treating depression.

Structure

MOL SDF PDB SMILES InChI

Synonyms

Not Available

Molecular Formula

C₁₁H₁₂N₂O₃

Average Mass

220.2246

Monoisotopic Mass

220.08479226

IUPAC Name

Not Available

Traditional Name

Not Available

CAS Registry Number

4350-09-8

SMILES

Not Available

InChI Identifier

InChI=1S/C11H12N2O3/c12-9(11(15)16)3-6-5-13-10-2-1-7(14)4-8(6)10/h1-2,4-5,9,13-14H,3,12H2,(H,15,16)/t9-/m0/s1

InChI Key

LDCYZAJDBXYCGN-VIFPVBQESA-N

Chemical Taxonomy

Functional Ontology

Not Available

Physical Properties

State

Solid

Predicted Properties

Not Available

Spectra

Not Available

Chromatographic Retention Times and Retention Indices

Retention Times

Chromatography Type	Technique	Column	Deposition Date	Retention Time (s)
Liquid Chromatography	HILIC	Waters Acquity UPLC-BEH Amide column (eluted)	2025-10-24	481.5
Liquid Chromatography	HILIC	Accucore 150 Amide HILIC (eluted)	2025-10-24	339.8
Liquid Chromatography	Reversed-phase	Hypersil Gold 1.9 µm C18 (eluted)	2025-10-24	65.8
Liquid Chromatography	Reversed-phase	Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) (eluted)	2025-10-24	224.2
Liquid Chromatography	Reversed-phase	XBridge C18 3.5u 2.1x50 mm (eluted)	2025-10-24	291.8
Liquid Chromatography	Reversed-phase	Ascentis Express C18 (void)	2025-10-24	260.7
Liquid Chromatography	Reversed-phase	Waters ACQUITY UPLC HSS T3 C18 (eluted)	2025-10-24	530.4
Liquid Chromatography	HILIC	Merck SeQuant ZIC-HILIC (eluted)	2025-10-24	855.4
Liquid Chromatography	HILIC	Merck SeQuant ZIC-pHILIC (eluted)	2025-10-24	441.7
Liquid Chromatography	Reversed-phase	Waters ACQUITY UPLC HSS T3 C18 (eluted)	2025-10-24	142.8
Liquid Chromatography	HILIC	Merck SeQuant ZIC-HILIC (eluted)	2025-10-24	502.8
Liquid Chromatography	Reversed-phase	Waters ACQUITY UPLC HSS T3 C18 (eluted)	2025-10-24	157.5
Liquid Chromatography	Reversed-phase	Waters ACQUITY UPLC BEH C18 (eluted)	2025-10-24	66.8
Liquid Chromatography	HILIC	Merck SeQuant ZIC-pHILIC column (eluted)	2025-10-24	387.5
Liquid Chromatography	HILIC	Merck SeQuant ZIC-pHILIC column (eluted)	2025-10-24	714.8
Liquid Chromatography	Reversed-phase	Waters ACQUITY UPLC BEH C18 (eluted)	2025-10-24	87.8
Liquid Chromatography	Reversed-phase	Waters ACQUITY UPLC BEH C18 (eluted)	2025-10-24	195.1
Liquid Chromatography	Reversed-phase	Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex (eluted)	2025-10-24	739.3
Liquid Chromatography	Reversed-phase	Waters Atlantis T3 (2.1 x 150 mm, 5 um) (eluted)	2025-10-24	574.0

Retention Indices

Chromatography Type	Peak Label	SMILES	Stationary Phase	Deposition Date	Retention Index
Gas Chromatography	5-Hydroxy-L-tryptophan_TMS_1	C[Si](C)(C)OC1=CC=C2[NH]C=C(C[C@H](N)C(=O)O)C2=C1	standard non polar	2025-10-24	2260.77
Gas Chromatography	5-Hydroxy-L-tryptophan_TMS_2	C[Si](C)(C)OC(=O)[C@@H](N)CC1=C[NH]C2=CC=C(O)C=C12	standard non polar	2025-10-24	1857.63
Gas Chromatography	5-Hydroxy-L-tryptophan_TMS_3	C[Si](C)(C)N[C@@H](CC1=C[NH]C2=CC=C(O)C=C12)C(=O)O	standard non polar	2025-10-24	2245.77
Gas Chromatography	5-Hydroxy-L-tryptophan_TMS_4	C[Si](C)(C)N1C=C(C[C@H](N)C(=O)O)C2=CC(O)=CC=C21	standard non polar	2025-10-24	2164.71
Gas Chromatography	5-Hydroxy-L-tryptophan_TMS_5	C[Si](C)(C)OC(=O)[C@@H](N)CC1=C[NH]C2=CC=C(O[Si](C)(C)C)C=C12	standard non polar	2025-10-24	1836.74
Gas Chromatography	5-Hydroxy-L-tryptophan_TMS_6	C[Si](C)(C)N[C@@H](CC1=C[NH]C2=CC=C(O[Si](C)(C)C)C=C12)C(=O)O	standard non polar	2025-10-24	1862.73
Gas Chromatography	5-Hydroxy-L-tryptophan_TMS_7	C[Si](C)(C)OC1=CC=C2C(=C1)C(C[C@H](N)C(=O)O)=CN2[Si](C)(C)C	standard non polar	2025-10-24	1836.67
Gas Chromatography	5-Hydroxy-L-tryptophan_TMS_8	C[Si](C)(C)N[C@@H](CC1=C[NH]C2=CC=C(O)C=C12)C(=O)O[Si](C)(C)C	standard non polar	2025-10-24	1317.54
Gas Chromatography	5-Hydroxy-L-tryptophan_TMS_9	C[Si](C)(C)OC(=O)[C@@H](N)CC1=CN([Si](C)(C)C)C2=CC=C(O)C=C12	standard non polar	2025-10-24	2352.88
Gas Chromatography	5-Hydroxy-L-tryptophan_TMS_10	C[Si](C)(C)N([C@@H](CC1=C[NH]C2=CC=C(O)C=C12)C(=O)O)[Si](C)(C)C	standard non polar	2025-10-24	1775.23
Gas Chromatography	5-Hydroxy-L-tryptophan_TMS_11	C[Si](C)(C)N[C@@H](CC1=CN([Si](C)(C)C)C2=CC=C(O)C=C12)C(=O)O	standard non polar	2025-10-24	2099.33
Gas Chromatography	5-Hydroxy-L-tryptophan_TMS_12	C[Si](C)(C)N[C@@H](CC1=C[NH]C2=CC=C(O[Si](C)(C)C)C=C12)C(=O)O[Si](C)(C)C	standard non polar	2025-10-24	1810.97
Gas Chromatography	5-Hydroxy-L-tryptophan_TMS_13	C[Si](C)(C)OC(=O)[C@@H](N)CC1=CN([Si](C)(C)C)C2=CC=C(O[Si](C)(C)C)C=C12	standard non polar	2025-10-24	2236.71
Gas Chromatography	5-Hydroxy-L-tryptophan_TMS_14	C[Si](C)(C)OC1=CC=C2[NH]C=C(C[C@@H](C(=O)O)N([Si](C)(C)C)[Si](C)(C)C)C2=C1	standard non polar	2025-10-24	2450.63
Gas Chromatography	5-Hydroxy-L-tryptophan_TMS_15	C[Si](C)(C)N[C@@H](CC1=CN([Si](C)(C)C)C2=CC=C(O[Si](C)(C)C)C=C12)C(=O)O	standard non polar	2025-10-24	1691.92
Gas Chromatography	5-Hydroxy-L-tryptophan_TMS_16	C[Si](C)(C)OC(=O)[C@H](CC1=C[NH]C2=CC=C(O)C=C12)N([Si](C)(C)C)[Si](C)(C)C	standard non polar	2025-10-24	2854.31
Gas Chromatography	5-Hydroxy-L-tryptophan_TMS_17	C[Si](C)(C)N[C@@H](CC1=CN([Si](C)(C)C)C2=CC=C(O)C=C12)C(=O)O[Si](C)(C)C	standard non polar	2025-10-24	1881.08
Gas Chromatography	5-Hydroxy-L-tryptophan_TMS_18	C[Si](C)(C)N([C@@H](CC1=CN([Si](C)(C)C)C2=CC=C(O)C=C12)C(=O)O)[Si](C)(C)C	standard non polar	2025-10-24	2590.08
Gas Chromatography	5-Hydroxy-L-tryptophan_TMS_19	C[Si](C)(C)OC(=O)[C@H](CC1=C[NH]C2=CC=C(O[Si](C)(C)C)C=C12)N([Si](C)(C)C)[Si](C)(C)C	standard non polar	2025-10-24	1661.74
Gas Chromatography	5-Hydroxy-L-tryptophan_TMS_20	C[Si](C)(C)N[C@@H](CC1=CN([Si](C)(C)C)C2=CC=C(O[Si](C)(C)C)C=C12)C(=O)O[Si](C)(C)C	standard non polar	2025-10-24	1643.68
Gas Chromatography	5-Hydroxy-L-tryptophan_TMS_21	C[Si](C)(C)OC1=CC=C2C(=C1)C(C[C@@H](C(=O)O)N([Si](C)(C)C)[Si](C)(C)C)=CN2[Si](C)(C)C	standard non polar	2025-10-24	1636.77
Gas Chromatography	5-Hydroxy-L-tryptophan_TMS_22	C[Si](C)(C)OC(=O)[C@H](CC1=CN([Si](C)(C)C)C2=CC=C(O)C=C12)N([Si](C)(C)C)[Si](C)(C)C	standard non polar	2025-10-24	1940.79
Gas Chromatography	5-Hydroxy-L-tryptophan_TMS_23	C[Si](C)(C)OC(=O)[C@H](CC1=CN([Si](C)(C)C)C2=CC=C(O[Si](C)(C)C)C=C12)N([Si](C)(C)C)[Si](C)(C)C	standard non polar	2025-10-24	2199.44
Gas Chromatography	5-Hydroxy-L-tryptophan_TMS_1	C[Si](C)(C)OC1=CC=C2[NH]C=C(C[C@H](N)C(=O)O)C2=C1	standard polar	2025-10-24	2100.62
Gas Chromatography	5-Hydroxy-L-tryptophan_TMS_2	C[Si](C)(C)OC(=O)[C@@H](N)CC1=C[NH]C2=CC=C(O)C=C12	standard polar	2025-10-24	2248.08
Gas Chromatography	5-Hydroxy-L-tryptophan_TMS_3	C[Si](C)(C)N[C@@H](CC1=C[NH]C2=CC=C(O)C=C12)C(=O)O	standard polar	2025-10-24	2216.4
Gas Chromatography	5-Hydroxy-L-tryptophan_TMS_4	C[Si](C)(C)N1C=C(C[C@H](N)C(=O)O)C2=CC(O)=CC=C21	standard polar	2025-10-24	2086.73
Gas Chromatography	5-Hydroxy-L-tryptophan_TMS_5	C[Si](C)(C)OC(=O)[C@@H](N)CC1=C[NH]C2=CC=C(O[Si](C)(C)C)C=C12	standard polar	2025-10-24	2258.3
Gas Chromatography	5-Hydroxy-L-tryptophan_TMS_6	C[Si](C)(C)N[C@@H](CC1=C[NH]C2=CC=C(O[Si](C)(C)C)C=C12)C(=O)O	standard polar	2025-10-24	3294.37
Gas Chromatography	5-Hydroxy-L-tryptophan_TMS_7	C[Si](C)(C)OC1=CC=C2C(=C1)C(C[C@H](N)C(=O)O)=CN2[Si](C)(C)C	standard polar	2025-10-24	2380.83
Gas Chromatography	5-Hydroxy-L-tryptophan_TMS_8	C[Si](C)(C)N[C@@H](CC1=C[NH]C2=CC=C(O)C=C12)C(=O)O[Si](C)(C)C	standard polar	2025-10-24	1803.03
Gas Chromatography	5-Hydroxy-L-tryptophan_TMS_9	C[Si](C)(C)OC(=O)[C@@H](N)CC1=CN([Si](C)(C)C)C2=CC=C(O)C=C12	standard polar	2025-10-24	2396.52
Gas Chromatography	5-Hydroxy-L-tryptophan_TMS_10	C[Si](C)(C)N([C@@H](CC1=C[NH]C2=CC=C(O)C=C12)C(=O)O)[Si](C)(C)C	standard polar	2025-10-24	2258.28
Gas Chromatography	5-Hydroxy-L-tryptophan_TMS_11	C[Si](C)(C)N[C@@H](CC1=CN([Si](C)(C)C)C2=CC=C(O)C=C12)C(=O)O	standard polar	2025-10-24	1909.21
Gas Chromatography	5-Hydroxy-L-tryptophan_TMS_12	C[Si](C)(C)N[C@@H](CC1=C[NH]C2=CC=C(O[Si](C)(C)C)C=C12)C(=O)O[Si](C)(C)C	standard polar	2025-10-24	953.583
Gas Chromatography	5-Hydroxy-L-tryptophan_TMS_13	C[Si](C)(C)OC(=O)[C@@H](N)CC1=CN([Si](C)(C)C)C2=CC=C(O[Si](C)(C)C)C=C12	standard polar	2025-10-24	1458.87
Gas Chromatography	5-Hydroxy-L-tryptophan_TMS_14	C[Si](C)(C)OC1=CC=C2[NH]C=C(C[C@@H](C(=O)O)N([Si](C)(C)C)[Si](C)(C)C)C2=C1	standard polar	2025-10-24	1718.1
Gas Chromatography	5-Hydroxy-L-tryptophan_TMS_15	C[Si](C)(C)N[C@@H](CC1=CN([Si](C)(C)C)C2=CC=C(O[Si](C)(C)C)C=C12)C(=O)O	standard polar	2025-10-24	1808.0
Gas Chromatography	5-Hydroxy-L-tryptophan_TMS_16	C[Si](C)(C)OC(=O)[C@H](CC1=C[NH]C2=CC=C(O)C=C12)N([Si](C)(C)C)[Si](C)(C)C	standard polar	2025-10-24	3013.53
Gas Chromatography	5-Hydroxy-L-tryptophan_TMS_17	C[Si](C)(C)N[C@@H](CC1=CN([Si](C)(C)C)C2=CC=C(O)C=C12)C(=O)O[Si](C)(C)C	standard polar	2025-10-24	1911.54
Gas Chromatography	5-Hydroxy-L-tryptophan_TMS_18	C[Si](C)(C)N([C@@H](CC1=CN([Si](C)(C)C)C2=CC=C(O)C=C12)C(=O)O)[Si](C)(C)C	standard polar	2025-10-24	1748.95
Gas Chromatography	5-Hydroxy-L-tryptophan_TMS_19	C[Si](C)(C)OC(=O)[C@H](CC1=C[NH]C2=CC=C(O[Si](C)(C)C)C=C12)N([Si](C)(C)C)[Si](C)(C)C	standard polar	2025-10-24	1516.51
Gas Chromatography	5-Hydroxy-L-tryptophan_TMS_20	C[Si](C)(C)N[C@@H](CC1=CN([Si](C)(C)C)C2=CC=C(O[Si](C)(C)C)C=C12)C(=O)O[Si](C)(C)C	standard polar	2025-10-24	3172.91
Gas Chromatography	5-Hydroxy-L-tryptophan_TMS_21	C[Si](C)(C)OC1=CC=C2C(=C1)C(C[C@@H](C(=O)O)N([Si](C)(C)C)[Si](C)(C)C)=CN2[Si](C)(C)C	standard polar	2025-10-24	1914.43
Gas Chromatography	5-Hydroxy-L-tryptophan_TMS_22	C[Si](C)(C)OC(=O)[C@H](CC1=CN([Si](C)(C)C)C2=CC=C(O)C=C12)N([Si](C)(C)C)[Si](C)(C)C	standard polar	2025-10-24	2026.11
Gas Chromatography	5-Hydroxy-L-tryptophan_TMS_23	C[Si](C)(C)OC(=O)[C@H](CC1=CN([Si](C)(C)C)C2=CC=C(O[Si](C)(C)C)C=C12)N([Si](C)(C)C)[Si](C)(C)C	standard polar	2025-10-24	1716.59

Biological Properties

Cellular Locations

Cytoplasm

Biospecimen Locations

Blood
Cerebrospinal Fluid (CSF)
Feces
Prostate
Urine

Tissue Locations

Prostate

Associated OMIM IDs

114500 (Colorectal cancer)
610247 (Eosinophilic esophagitis)

Human Proteins and Enzymes

Protein ID	Protein Name	Protein Type	Uniprot ID	Species
MMDBp0191948	Aromatic-L-amino-acid decarboxylase	Enzyme	P20711	Homo sapiens
MMDBp0192103	Indoleamine 2,3-dioxygenase 1	Unknown	P14902	Homo sapiens
MMDBp0192127	Tryptophan 5-hydroxylase 1	Enzyme	P17752	Homo sapiens
MMDBp0192129	Tryptophan 5-hydroxylase 2	Enzyme	Q8IWU9	Homo sapiens
MMDBp0193303	Aryl hydrocarbon receptor	Unknown	P35869	Homo sapiens
MMDBp0194191	Indoleamine 2,3-dioxygenase 2	Unknown	Q6ZQW0	Homo sapiens

Human Pathways

Pathways

Name	SMPDB/PathBank

Microbial Pathways

Pathways

Not Available

Metabolic Reactions

Reactions

This table shows at most 20 reactions. For the full list of associated reactions:

See All Associated Reactions

Reaction ID	Precursor	Product	Enzyme	Reaction Type	Data Source	Reference

Health Effects and Bioactivity

Health Outcome/Bioactivity	Metabolite Response/Effect	Evidence Type	Host and Biospecimen	Data Source	Reference
Aromatic l-amino acid decarboxylase deficiency		Association	Human Cerebrospinal Fluid (CSF)	HMDB	9686366

Microbial Sources

Superkingdom/Kingdom	Phylum	Total species	Hosts and Body Sites	Microbial Links
Bacteria/Eubacteria	Firmicutes	89	Human feces; Pig ; Human ; Cattle	Metabolic reconstruction
Bacteria/Eubacteria	Proteobacteria	207	Human feces; Human sputum; Human ; Human unknown; Pig ; Human pleural fluid plaque; Human dental plaque; Human nasal swab	Metabolic reconstruction
Bacteria/Eubacteria	Actinobacteria	86	Human feces; Human ; Human supragingival plaque	Metabolic reconstruction
Bacteria/Eubacteria	Bacteroidetes	6	Human feces	Metabolic reconstruction
Archaea	Euryarchaeota	2		Metabolic reconstruction
Bacteria/Eubacteria	Fusobacteria	2	Human ; Human feces	Metabolic reconstruction
Bacteria/Eubacteria	Planctomycetes	2	Human feces	Metabolic reconstruction

Exposure Sources

Other Exposures

Source Type	Data Source	Reference
Drugs - Antimicrobial	U.S. Environmental Protection Agency	CompTox
Cosmetics	U.S. Environmental Protection Agency	CompTox
Domestics	U.S. Environmental Protection Agency	CompTox

Host Biospecimen and Location

Host and Biospecimen	Status	Mean	Std	Min	Max	Units	Age	Sex	Health Condition	Data Source	Reference
Human Feces	Detected but not Quantified									HMDB
Human Cerebrospinal fluid (csf)	Detected and Quantified	0.063				uM	Infant (0-1 year old)	Female	Aromatic L-amino acid decarboxylase deficiency	HMDB	9686366
Human Cerebrospinal fluid (csf)	Detected and Quantified			0.0970	0.136	uM	Children (1-13 years old)	Female	Aromatic L-amino acid decarboxylase deficiency	HMDB	9686366
Human Urine	Detected and Quantified	0.0078				umol/mmol creatinine	Adult (>18 years old)	Both	Normal	HMDB	19309105
Human Cerebrospinal fluid (csf)	Detected and Quantified	<0.0100				uM	Children (1-13 years old)	Female	Normal	HMDB	9686366
Human Cerebrospinal fluid (csf)	Detected and Quantified	0.005		0.00	0.010	uM	Infant (0-1 year old)	Both	Normal	HMDB	11486900
Human Blood	Detected and Quantified	0.018	0.0027			uM	Adult (>18 years old)	Both	Normal	HMDB	11910264
Human Prostate	Detected but not Quantified						Not Specified	Not Specified	Normal	HMDB	34986597
Human Urine	Detected but not Quantified						Adult (>18 years old)	Both	Normal	HMDB	32966057
Human Blood	Detected but not Quantified						Adult (>18 years old)	Both	Normal	HMDB	32966057

External Links

HMDB ID

Not Available

DrugBank ID

Not Available

Phenol Explorer Compound ID

Not Available

FooDB ID

Not Available

KNApSAcK ID

Not Available

Chemspider ID

Not Available

KEGG Compound ID

Not Available

BioCyc ID

Not Available

BiGG ID

Not Available

Wikipedia Link

Not Available

METLIN ID

Not Available

PubChem Compound

Not Available

PDB ID

Not Available

ChEBI ID

Not Available

Food Biomarker Ontology

Not Available

CMMC Knowledgebase

Not Available

General References

Bouchard S, Roberge AG: Biochemical properties and kinetic parameters of dihydroxyphenylalanine--5-hydroxytryptophan decarboxylase in brain, liver, and adrenals of cat. Can J Biochem. 1979 Jul;57(7):1014-8. doi: 10.1139/o79-126. [PubMed:39668 ]
Amamoto T, Sarai K: On the tryptophan-serotonin metabolism in manic-depressive disorders. Changes in plasma 5-HT and 5-HIAA levels and urinary 5-HIAA excretion following oral loading of L-5HTP in patients with depression. Hiroshima J Med Sci. 1976 Sep;25(2-3):135-40. [PubMed:1088369 ]
Caruso I, Sarzi Puttini P, Cazzola M, Azzolini V: Double-blind study of 5-hydroxytryptophan versus placebo in the treatment of primary fibromyalgia syndrome. J Int Med Res. 1990 May-Jun;18(3):201-9. doi: 10.1177/030006059001800304. [PubMed:2193835 ]
De Benedittis G, Massei R: Serotonin precursors in chronic primary headache. A double-blind cross-over study with L-5-hydroxytryptophan vs. placebo. J Neurosurg Sci. 1985 Jul-Sep;29(3):239-48. [PubMed:3913752 ]
Magnussen I, Jensen TS, Rand JH, Van Woert MH: Plasma accumulation of metabolism of orally administered single dose L-5-hydroxytryptophan in man. Acta Pharmacol Toxicol (Copenh). 1981 Sep;49(3):184-9. doi: 10.1111/j.1600-0773.1981.tb00890.x. [PubMed:6175178 ]
Magnussen I, Van Woert MH: Human pharmacokinetics of long term 5-hydroxytryptophan combined with decarboxylase inhibitors. Eur J Clin Pharmacol. 1982;23(1):81-6. doi: 10.1007/BF01061381. [PubMed:6182005 ]
Rahman MK, Nagatsu T, Sakurai T, Hori S, Abe M, Matsuda M: Effect of pyridoxal phosphate deficiency on aromatic L-amino acid decarboxylase activity with L-DOPA and L-5-hydroxytryptophan as substrates in rats. Jpn J Pharmacol. 1982 Oct;32(5):803-11. doi: 10.1254/jjp.32.803. [PubMed:6983619 ]
Sternberg EM, Van Woert MH, Young SN, Magnussen I, Baker H, Gauthier S, Osterland CK: Development of a scleroderma-like illness during therapy with L-5-hydroxytryptophan and carbidopa. N Engl J Med. 1980 Oct 2;303(14):782-7. doi: 10.1056/NEJM198010023031403. [PubMed:6997735 ]
Trouillas P, Serratrice G, Laplane D, Rascol A, Augustin P, Barroche G, Clanet M, Degos CF, Desnuelle C, Dumas R, et al.: Levorotatory form of 5-hydroxytryptophan in Friedreich's ataxia. Results of a double-blind drug-placebo cooperative study. Arch Neurol. 1995 May;52(5):456-60. doi: 10.1001/archneur.1995.00540290042016. [PubMed:7733839 ]
Li Kam Wa TC, Freestone S, Samson RR, Johnson NR, Lee MR: A comparison of the renal and neuroendocrine effects of two 5-hydroxytryptamine renal prodrugs in normal man. Clin Sci (Lond). 1993 Nov;85(5):607-14. doi: 10.1042/cs0850607. [PubMed:8287650 ]
Li Kam Wa TC, Freestone S, Samson RR, Johnston NR, Lee MR: Renal metabolism and effects of the glutamyl derivatives of L-dopa and 5-hydroxytryptophan in man. Clin Sci (Lond). 1996 Aug;91(2):177-85. doi: 10.1042/cs0910177. [PubMed:8795441 ]
Iacono RP, Kuniyoshi SM, Ahlman JR, Zimmerman GJ, Maeda G, Pearlstein RD: Concentrations of indoleamine metabolic intermediates in the ventricular cerebrospinal fluid of advanced Parkinson's patients with severe postural instability and gait disorders. J Neural Transm (Vienna). 1997;104(4-5):451-9. doi: 10.1007/BF01277663. [PubMed:9295177 ]
Birdsall TC: 5-Hydroxytryptophan: a clinically-effective serotonin precursor. Altern Med Rev. 1998 Aug;3(4):271-80. [PubMed:9727088 ]
Shaw K, Turner J, Del Mar C: Tryptophan and 5-hydroxytryptophan for depression. Cochrane Database Syst Rev. 2002;(1):CD003198. doi: 10.1002/14651858.CD003198. [PubMed:11869656 ]
Turner EH, Blackwell AD: 5-Hydroxytryptophan plus SSRIs for interferon-induced depression: synergistic mechanisms for normalizing synaptic serotonin. Med Hypotheses. 2005;65(1):138-44. doi: 10.1016/j.mehy.2005.01.026. [PubMed:15893130 ]
Turner EH, Loftis JM, Blackwell AD: Serotonin a la carte: supplementation with the serotonin precursor 5-hydroxytryptophan. Pharmacol Ther. 2006 Mar;109(3):325-38. doi: 10.1016/j.pharmthera.2005.06.004. Epub 2005 Jul 14. [PubMed:16023217 ]
Verbeek MM, Geurtz PB, Willemsen MA, Wevers RA: Aromatic L-amino acid decarboxylase enzyme activity in deficient patients and heterozygotes. Mol Genet Metab. 2007 Apr;90(4):363-9. doi: 10.1016/j.ymgme.2006.12.001. Epub 2007 Jan 19. [PubMed:17240182 ]
Nakatani Y, Sato-Suzuki I, Tsujino N, Nakasato A, Seki Y, Fumoto M, Arita H: Augmented brain 5-HT crosses the blood-brain barrier through the 5-HT transporter in rat. Eur J Neurosci. 2008 May;27(9):2466-72. doi: 10.1111/j.1460-9568.2008.06201.x. [PubMed:18445233 ]
Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, Laxman B, Mehra R, Lonigro RJ, Li Y, Nyati MK, Ahsan A, Kalyana-Sundaram S, Han B, Cao X, Byun J, Omenn GS, Ghosh D, Pennathur S, Alexander DC, Berger A, Shuster JR, Wei JT, Varambally S, Beecher C, Chinnaiyan AM: Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature. 2009 Feb 12;457(7231):910-4. doi: 10.1038/nature07762. [PubMed:19212411 ]

Showing metabocard for 5-Hydroxy-L-tryptophan (MMDBc0047911)

MOL for #<Metabolite:0x00007f9acc9cb3c8>

3D MOL for #<Metabolite:0x00007f9acc9cb3c8>

3D SDF for #<Metabolite:0x00007f9acc9cb3c8>

3D-SDF for #<Metabolite:0x00007f9acc9cb3c8>

PDB for #<Metabolite:0x00007f9acc9cb3c8>

3D PDB for #<Metabolite:0x00007f9acc9cb3c8>

SMILES for #<Metabolite:0x00007f9acc9cb3c8>

INCHI for #<Metabolite:0x00007f9acc9cb3c8>

Structure for #<Metabolite:0x00007f9acc9cb3c8>

3D Structure for #<Metabolite:0x00007f9acc9cb3c8>